Author: Suzanne B. Robotti

Suzanne B. Robotti

Suzanne is the President and Founder of MedShadow, and the Executive Director of DES Action USA.  MedShadow’s mission is to preserve quality of life by ensuring everyone has access to the risks, benefits and alternates to using drugs to manage healthcare. Read More

As an independent health-driven nonprofit, MedShadow’s mission is to ensure that all people have information on the risks and benefits of medicines and treatments, so they can make the best health care choices for themselves and their families. Separate from any personal, political or religious beliefs, the ruling from the Supreme Court on June 24, 2022 overturning Roe v. Wade has far-reaching health implications.   MedShadow considers pregnancy and abortion solely from the perspective of health care. Pregnancy is not a benign process. It changes every system in the body from circulatory (the amount of blood in your body increases by…

Read More

Bob R.’s New York City doctor told him his cholesterol was high and prescribed statins. After taking the statins for two years, Bob was feeling muscle pains and had read about the possible cognitive declines tied to statins. At his next physical, Bob told his doctor he wanted to stop the statins and try exercising a little more, drop a few pounds and see if that lowered his cholesterol. The doctor agreed and noted, “You’re borderline on needing statins anyway.” Yikes! Who knew that? Bob hadn’t questioned the overdiagnosing or the treatment. He took statins and experienced the side effects,…

Read More

Editor’s Note 11/23/2021: Researchers recently published data showing that 41% of patients on the therapeutic dose of Adhuhelm in clinical trials experienced brain bleeds. Fewer than a third of those patients experienced symptoms. The New York Times reported one death under investigation. Some researchers worry that clinical trial participants were much healthier and therefore not representative of patients now likely to be prescribed the drug.  The newly approved drug Aduhelm (aducanumab) won’t cure or reverse the effects of Alzheimer’s disease. It might slow the disease’s progression, but there’s no proof that it will do that either. Even worse is that…

Read More

If your chemotherapy cancer drugs are making you feel miserable, you might be able to have your dose lowered without it losing effectiveness.  The dose makes the poison, noted the Swiss chemist Paracelsus more than 500 years ago. For example, you could take two acetaminophen pills (Tylenol) for a headache and get good relief, or you could take 20 of them and end up in the hospital, having poisoned yourself and harmed your kidneys. Or you might simply drink two glasses of water, take a walk and then notice that  your headache has gone away without taking any medicine. The…

Read More

The Food and Drug Administration (FDA) has now approved the diabetes drug Wegovy (semaglutide), previously okayed for diabetes, for weight loss. I wonder why? I was the consumer representative on the FDA advisory panel that voted to approve Wegovy (semaglutide) for diabetes. I voted for it reluctantly and only because the drug helped slightly improve life for those with diabetes. A small weight loss is one benefit of Wegovy. Patients given Wegovy in clinical trials lost between five and ten pounds. That’s helpful for a person with type-2 diabetes, but for the average person, it is a minor change in…

Read More

Happy Independence Day weekend! This is the most important holiday to MedShadow because we celebrate our ongoing independence from pharmaceutical influence.  We are one of the few, free, nonprofit sites that refuses pharma money because we are committed to giving you the unbiased, honest facts of health that you need to keep yourself and your family safer from medical harm.  Misleading information, even lies, from drug companies is nothing new and a reality across our nation’s history. In the winter of 1905, Mark Twain himself sent the world’s most eloquent angry letter to a drug company selling bogus patent medicine…

Read More